This skill recommends longitudinal monitoring and rigorous management of identified comorbidities—such as hypertension, diabetes mellitus, cardiovascular disease, osteoarthritis, and sleep apnea—in patients with acromegaly. Apply throughout follow‑up when comorbidities are present to mitigate morbidity and mortality risk.
Installs into .claude/skills of the current project.
Are you the author of Endo Comorbidities Longitudinal Monitoring?
Add the live security badge to your README. It updates with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-endo-comorbidities-longitudinal-monitoring)
---
name: endo-comorbidities-longitudinal-monitoring
description: This skill recommends longitudinal monitoring and rigorous management of identified comorbidities—such as hypertension, diabetes mellitus, cardiovascular disease, osteoarthritis, and sleep apnea—in patients with acromegaly. Apply throughout follow‑up when comorbidities are present to mitigate morbidity and mortality risk.
---
# Longitudinally monitor and manage comorbidities
## STEP 1 — Gather Information
Collect baseline comorbidity data: blood pressure, fasting glucose/HbA1c, lipid panel, cardiovascular risk assessment, sleep apnea screening (e.g., STOP‑BANG or Epworth), joint symptom review, and physical exam for edema or arthropathy.
## STEP 2 — Rule In / Rule Out
Determine if any comorbidity is present; if **yes**, proceed to stratification; if **no**, continue routine acromegaly follow‑up without intensified comorbidity monitoring.
## STEP 3 — Classify or Stratify
For each identified comorbidity, classify severity: hypertension (stage 1/2), diabetes (HbA1c target <7% or individualized), sleep apnea (mild/moderate/severe by AHI), osteoarthritis (pain/function impact), cardiovascular disease (existing CAD, HF, arrhythmia).
## STEP 4 — Decide
Initiate or intensify disease‑specific management per guidelines (e.g., start antihypertensive, optimize glycemic control, refer for sleep study/CPAP, joint referral, cardiology) and set monitoring interval (typically every 3–6 months) alongside acromegaly treatment.
## Clinical Guardrails / Mimics / Pitfalls
Do not assume comorbidities will resolve with GH/IGF‑1 control alone; avoid delaying hypertension/diabetes treatment awaiting biochemical remission; do not rely solely on symptomatic improvement; watch for medication interactions (e.g., SRLs affecting glucose); do not neglect colon neoplasia screening when indicated.
## Concrete Clinical Example
A 45‑year‑old with newly diagnosed acromegaly presents with BP 148/92 mmHg, HbA1c 6.8%, and daytime fatigue. After confirming hypertension, prediabetes, and high STOP‑BANG score, start lisinopril, metformin, refer for polysomnography, and schedule combined acromegaly/comorbidity follow‑up in 3 months.
**Source:** Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
